OPKO Health Inc. (OPK)
OPK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/944809/000119312526076596/0001193125-26-076596-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | OPK on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000944809 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $606.9M |
| Net income | -$225.7M |
| Operating income | -$117.4M |
| Net margin | -37.2% |
| Operating margin | -19.3% |
| Revenue growth | -14.9% |
| Cash | $364.4M |
| Total assets | $1.9B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $384.0M cash; operating cash flow -$31.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 742,506,477 (2026-10-20); 767,701,280 a year earlier; 773,056,533 three years earlier. | Cover page 2026-10-20 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Miami, Florida, United States | PCAOB Form AP 2026-03-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $3.2M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $65.4M | -$53.5M | -$36.3M | $384.0M | $477.4M | $501.6M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $163.6M | -$8.4M | -$43.5M | $300.8M | $349.1M | $492.7M | 10-Q/A 2026-08-28 |
| Q1 2026 2026-03-31 | $124.2M | -$54.8M | -$19.3M | $331.9M | $345.7M | $485.9M | 10-Q/A 2026-08-28 |
| Q4 2025 2025-12-31 | $148.5M | -$31.3M | -$25.9M | $364.4M | $344.0M | $511.6M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $56.4M | $21.6M | -$34.6M | $412.0M | $344.2M | $546.8M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $156.8M | -$148.4M | -$83.4M | $267.3M | $343.3M | $664.0M | 10-Q/A 2026-08-28 |
| Q1 2025 2025-03-31 | $150.0M | -$67.6M | -$34.6M | $428.8M | $439.2M | $689.4M | 10-Q/A 2026-08-28 |
| Q4 2024 2024-12-31 | $183.6M | $14.0M | -$44.4M | $426.6M | $437.2M | $713.1M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2019-10-25 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-05-15 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.9% |
| 1 month | +27.3% |
| 3 months | +20.0% |
| Year to date | +33.3% |
| 1 year | +31.3% |
| From 52-week high | -5.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KARD | Kardigan Inc. | $12.85 | -7.02% | $1.2B |
| OMER | Omeros Corporation | $16.68 | -4.63% | $1.2B |
| SLN | Silence Therapeutics Plc American Depository Share | $19.80 | -0.15% | $1.2B |
| CMPS | COMPASS Pathways Plc American Depository Shares | $8.27 | -8.21% | $1.2B |
| AAPG | Ascentage Pharma Group International American Depository Shares | $13.29 | -9.10% | $1.2B |
| AMPH | Amphastar Pharmaceuticals Inc. | $29.17 | -0.68% | $1.2B |
| NKTR | Nektar Therapeutics | $36.44 | -2.23% | $1.2B |
| MNKD | MannKind Corporation | $3.96 | -4.24% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier